权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis

液体活检中的聚糖生物标志物组用于预测狼疮性肾炎的治疗反应

基本信息

批准号：
10601270
负责人：
Stephen Castellino
金额：
$ 27.54万
依托单位：
GLYCOPATH, INC
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-15 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10601270
关键词：
Address Affect Amines Anti-Inflammatory Agents Antibodies Antigen-Antibody Complex Asparagine Autoimmune Diseases Biological Assay Biological Markers Cells Chronic Clinic Clinical Collaborations Data Diagnostic Disease End stage renal failure Glomerulonephritis Glycoproteins IgG1 IgG2 IgG3 IgG4 Immune Complex Diseases Immunoglobulin G Immunoglobulins Immunosuppression In complete remission Inflammatory Response Joints Kidney Transplantation Legal patent Licensing Link Lung Transplantation Lupus Nephritis Mediating Metadata Methods Modification Monitor Nephrology Organ Outcome Parents Patients Peptide N-glycohydrolase F Peripheral Phase Physicians Plasma Polysaccharides Prediction of Response to Therapy Property Publishing Reporting Sampling Serum Slide Small Business Technology Transfer Research Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Spottings Systemic Lupus Erythematosus Testing Therapeutic Time Tissues Treatment Protocols Urine biobank biomarker panel clinical translation cohort follow-up glycosylation immunoregulation liquid biopsy mycophenolate mofetil patient subsets predicting response profiles in patients response standard care standard of care sugar treatment response

项目摘要

Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed treatment decisions for LN patients. To address this, our proposal builds upon ongoing collaborations between a clinical nephrology group at MUSC with an extensive LN biorepository of control and treatment samples with clinical metadata and GlycoPath Inc., a diagnostic company developing unique glycosylation targeted liquid biopsy assays. GlycoPath has recently patented, licensed and published a streamlined antibody capture slide array approach, GlycoTyper, to directly profile N-glycans of captured serum and plasma glycoproteins including imm unoglobulin G (IgG) subtypes. An adaption of the GlycoTyper platform has also been developed to rapidly obtain total glycan profiles of biofluids like serum and urine. Using this approach, several cohorts of patient matched serum and urine from control and LN subjects have been evaluated for N-linked glycan constituents. A distinct panel of LN associated N- glycans have already been identified and serve as the basis for the proposed studies. Because we can use glycan panels to distinguish control from LN conditions, we hypothesize that this assay can be applied to monitor treatment response in biofluids from subjects treated with standard-of-care therapies like mycophenolate mofetil (MMF). In this Phase I STTR application, we propose to establish the technical merit and feasibility of Glycotyper-LNTx for monitoring LN treatment responses. Aim 1 will validate N-glycan profiles in urine samples from LN subjects for MMF treatment response at time zero, 3 months and 12 months of treatment. Aim 2 will identify IgG specific N-glycan profiles in patient matched serum and urine samples with follow up application in a LN treatment response cohort. This study will establish and validate a LN specific liquid biopsy glycan biomarker assay for use in monitoring disease status and therapeutic response.

狼疮性肾炎（LN），一种免疫复合物介导的肾小球肾炎，影响多达三分之二的患者